Literature DB >> 25994521

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity.

A Rodríguez-García1, E Svensson2, R Gil-Hoyos1, C A Fajardo1, L A Rojas1, M Arias-Badia1, A S I Loskog2, R Alemany1.   

Abstract

Oncolytic adenoviruses can promote immune responses against tumors by expressing and/or displaying tumor-associated antigens. However, the strong immunodominance of viral antigens mask responses against tumor epitopes. In addition, defects in major histocompatibility complex class I antigen presentation pathway such as the downregulation of the transporter-associated with antigen processing (TAP) are frequently associated with immune evasion of tumor cells. To promote the immunogenicity of exogenous epitopes in the context of an oncolytic adenovirus, we have taken advantage of the ER localization of the viral protein E3-19K. We have inserted tumor-associated epitopes after the N-terminal signal sequence for membrane insertion of this protein and flanked them with linkers cleavable by the protease furin to facilitate their TAP-independent presentation. This strategy allowed an enhanced presentation of the exogenous epitopes in TAP-deficient tumor cells in vitro and the generation of higher specific immune responses in vivo that were able to significantly control tumor growth.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994521     DOI: 10.1038/gt.2015.41

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

1.  Generation of MHC class I peptide antigens by protein processing in the secretory route by furin.

Authors:  B C Gil-Torregrosa; A R Castaño; D López; M Del Val
Journal:  Traffic       Date:  2000-08       Impact factor: 6.215

2.  Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.

Authors:  H T Maecker; D T Umetsu; R H DeKruyff; S Levy
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity.

Authors:  Hong Jiang; Erin J White; Christian I Ríos-Vicil; Jing Xu; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  Adenoviruses induce autophagy to promote virus replication and oncolysis.

Authors:  Humberto Rodriguez-Rocha; Jorge G Gomez-Gutierrez; Aracely Garcia-Garcia; Xiao-Mei Rao; Lan Chen; Kelly M McMasters; Heshan Sam Zhou
Journal:  Virology       Date:  2011-05-14       Impact factor: 3.616

Review 5.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.

Authors:  Patrizia Leone; Eui-Cheol Shin; Federico Perosa; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  J Natl Cancer Inst       Date:  2013-07-12       Impact factor: 13.506

6.  IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.

Authors:  Matteo Martini; Maria Grazia Testi; Matteo Pasetto; Maria Cristina Picchio; Giulio Innamorati; Marta Mazzocco; Stefano Ugel; Sara Cingarlini; Vincenzo Bronte; Paola Zanovello; Mauro Krampera; Federico Mosna; Tiziana Cestari; Anna Pia Riviera; Nadia Brutti; Ottavia Barbieri; Lina Matera; Giuseppe Tridente; Marco Colombatti; Silvia Sartoris
Journal:  Vaccine       Date:  2010-03-19       Impact factor: 3.641

7.  Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures.

Authors:  C Winzler; P Rovere; M Rescigno; F Granucci; G Penna; L Adorini; V S Zimmermann; J Davoust; P Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

8.  Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.

Authors:  Hung T Khong; Qiong J Wang; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 May-Jun       Impact factor: 4.456

9.  Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting.

Authors:  Neus Bayo-Puxan; Marta Gimenez-Alejandre; Sergio Lavilla-Alonso; Alena Gros; Manel Cascallo; Akseli Hemminki; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

10.  Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma.

Authors:  Shefali Agrawal; Keith Reemtsma; Emilia Bagiella; Soji F Oluwole; Ned S Braunstein
Journal:  Cell Immunol       Date:  2004-04       Impact factor: 4.868

View more
  5 in total

1.  Codon optimization of the adenoviral fiber negatively impacts structural protein expression and viral fitness.

Authors:  Eneko Villanueva; Maria Martí-Solano; Cristina Fillat
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

Review 2.  CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.

Authors:  Sonia Guedan; Ramon Alemany
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

Review 3.  Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.

Authors:  Amirhossein Mardi; Anastasia V Shirokova; Rebar N Mohammed; Ali Keshavarz; Angelina O Zekiy; Lakshmi Thangavelu; Talar Ahmad Merza Mohamad; Faroogh Marofi; Navid Shomali; Amir Zamani; Morteza Akbari
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

Review 4.  Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.

Authors:  Ramazan Rezaei; Hadi Esmaeili Gouvarchin Ghaleh; Mahdieh Farzanehpour; Ruhollah Dorostkar; Reza Ranjbar; Masoumeh Bolandian; Majid Mirzaei Nodooshan; Akbar Ghorbani Alvanegh
Journal:  Cancer Gene Ther       Date:  2021-06-22       Impact factor: 5.854

Review 5.  Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.

Authors:  Dong Ho Shin; Teresa Nguyen; Bulent Ozpolat; Frederick Lang; Marta Alonso; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 12.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.